Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV):use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3 by Simmonds, P et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mapping of serotype-specific, immunodominant epitopes in the
NS-4 region of hepatitis C virus (HCV)
Citation for published version:
Simmonds, P, Rose, KA, Graham, S, Chan, SW, McOmish, F, Dow, BC, Follett, EA, Yap, PL & Marsden, H
1993, 'Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus
(HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3'
Journal of Clinical Microbiology, vol 31, no. 6, pp. 1493-503.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher final version (usually the publisher pdf)
Published In:
Journal of Clinical Microbiology
Publisher Rights Statement:
Copyright © 1993, American Society for Microbiology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
JOURNAL OF CLINICAL MICROBIOLOGY, June 1993, p. 1493-1503
0095-1137/93/061493-11$02.00/0
Copyright © 1993, American Society for Microbiology
Mapping of Serotype-Specific, Immunodominant Epitopes in
the NS-4 Region of Hepatitis C Virus (HCV): Use of
Type-Specific Peptides To Serologically Differentiate
Infections with HCV Types 1, 2, and 3
P. SIMMONDS,l* K. A. ROSE,2 S. GRAHAM,3 S.-W. CHAN,1 F. McOMISH,2 B. C. DOW,4
E. A. C. FOLLETT,4 P. L. YAP,2 AND H. MARSDEN3
Department ofMedical Microbiology, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG';
Edinburgh and South East Scotland Blood Transfusion Service, Edinburgh EH3 9HB2; Medical
Research Council Virology Unit, University of Glasgow, Glasgow Gil SJR3; and Scottish
National Blood Transfusion Service Microbiology Reference Unit, Ruchill Hospital,
Glasgow G20 9NB,4 United Kingdom
Received 14 December 1992/Accepted 16 March 1993
The effect of sequence variability between different types of hepatitis C virus (HCV) on the antigenicity of the
NS-4 protein was investigated by epitope mapping and by enzyme-linked immunosorbent assay with branched
oligopeptides. Epitope mapping of the region between amino acid residues 1679 and 1768 in the HCV
polyprotein revealed two major antigenic regions (1691 to 1708 and 1710 to 1728) that were recognized by
antibody elicited upon natural infection of HCV. The antigenic regions were highly variable between variants
of HCV, with only 50 to 60%o amino acid sequence similarity between types 1, 2, and 3. Although limited
serological cross-reactivity between HCV types was detected between peptides, particularly in the first
antigenic region of NS-4, type-specific reactivity formed the principal component of the natural humoral
immune response to NS-4. Type-specific antibody to particular HCV types was detected in 89%o of the samples
from anti-HCV-positive blood donors and correlated almost exactly with genotypic analysis of HCV sequences
amplified from the samples by polymerase chain reaction. Whereas almost all blood donors appeared to be
infected with a single virus type (97%), a higher proportion of samples (40%) from hemophiliacs infected from
transfusion of non-heat-inactivated clotting factor contained antibody to two or even all three HCV types,
providing evidence that long-term exposure may lead to multiple infection with different variants of HCV.
The identification of hepatitis C virus (HCV) (9) and the
development of serological assays to detect infection in
blood donors (24) provide an important opportunity for
prevention of posttransfusion non-A, non-B hepatitis
(NANBH). Early serological assays used the NS-4-derived
recombinant protein, clOO-3, as an antigen on the solid phase
in an indirect enzyme-linked immunosorbent assay (ELISA).
This test was of major value in early surveys of the incidence
of HCV infection in different risk groups for infection (11),
such as patients with posttransfusion NANBH and implicated
donors (2, 16, 54) and hemophiliacs (4, 15, 27, 29). However,
the test yielded frequent false-positive reactions (44), partic-
ularly with samples containing autoantibodies (21, 31, 49). In
the absence of a satisfactoxy confirmatory assay, particularly
misleading results were obtained when the assay was used to
screen populations with a low incidence of infection, such as
volunteer blood donors (12, 34).
However, a more serious problem was the frequent occur-
rence of false-negative results. An indication of the relative
insensitivity of the test was provided by the finding that not
all hemophiliacs treated with non-heat-inactivated factor
VIII or IX were anti-ClO0 positive despite suffering from
NANBH (4, 15, 27, 29). That HCV was responsible was
demonstrated by the frequent detection of circulating RNA
in plasma by the polymerase chain reaction (PCR) in sero-
negative hemophiliacs (43), particularly those with concur-
rent infection with human immunodeficiency virus. In retro-
* Corresponding author.
spective studies of posttransfusion NANBH patients, a
considerable delay was found between transfusion and the
onset of hepatitis with the development of antibody to clOO-3
(6 weeks to 6 months) (2, 16, 26, 51, 53, 55, 57). Transfusion
of blood collected during this period may account for many
of the continued transmissions of HCV to blood recipients
(16, 22) after anti-ClO0 assays were adopted for blood
donation screening.
Another possible cause for the absence of reactivity to
clOO-3 in infected individuals could be the sequence variabil-
ity of different HCV isolates in the NS-4 region. Hepatitis C
viruses are a heterogeneous group of viruses, which make up
several major types (7, 14, 35, 50) showing approximately
70% homology overall, similar to that which exists between
different serotypes of other flaviviruses (6). Currently, three
major types have been characterized in detail and will be
referred to here as HCV type 1 (10, 23, 46), type 2 (37, 38)
and type 3 (7, 35), as recently proposed (7). Each major type
can in turn be further differentiated into a number of sub-
types, termed la, lb, and 2a, etc. When complete sequence
data are available, it has been found that the subtypes show
77 to 79% similarity, consistently greater than that found
between the major types of HCV. We have evidence for at
least four subtypes of type 1 and three subtypes of type 2
(19a), while comparative sequence data of HCV type 3
variants in the NS-5 region reveal two subtypes (35).
The NS-4 region encoding the clOO-3 antigen is variable
between different isolates of HCV, showing only 75 to 77%
sequence similarity between HCV types 1 and 2. That this
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TABLE 1. Sequences of primers used for amplification of the NS-4 region of HCV types 1, 2, and 3
Primer HCV typea Position' Orientationc Sequence 5' to 3'
007 All 5293 AACTCGAGTATCCCACTGATGAAGTTCCACAT
220 All 5278 CACATGTGCTTCGCCCAGAA
253 1 4858 + GGGCCAACACCCCTGCTATA
196 1 4878 + CAGACTGGGCGCCGTTCAGAATG
281 2 4858 + GGTCCCACCCCTCTCCTGTA
509 2 4878 + CCGCTTGGGTTCCGTTACCAACG
221 3 4858 + GGACCTACGCCCCTTCTATA
008 3 4878 + TCGGTTGGGGCCTGTCCAAAATG
a Separate sense primers required to enable amplification of each HCV type.
b Position of the 5' base relative to the HCV genomic sequence given in reference 10.
Orientation of primer sequence (+, sense; -, antisense).
affects serological recognition is shown by the relatively
infrequent serological reactivity of sera from blood donors
infected with HCV types 2 and 3 with NS-4-derived antigens
in immunoblot assays (7, 33) and frequent negative results in
the original first generation blood donor screening assays. In
the current study, we have investigated the distribution of
epitopes in the NS-4 region encoding clOO-3 for HCV types
1, 2, and 3. The frequency of serological reactivity to
synthetic peptides corresponding to two antigenic regions of
the sequenced region of the three HCV types was investi-
gated with samples from blood donors infected with known
HCV types. This allowed an investigation of the frequency
of type-specific and cross-reactive antibody specificities to
be determined in naturally infected individuals. Finally, an
assay for type-specific antibody provided evidence for infec-
tion with different HCV types in anti-HCV-positive blood
donors and a higher incidence of mixed infection in hemo-
philiacs multiply exposed to HCV.
MATERIALS AND METHODS
Samples. Plasma samples were obtained from 137 HCV-
infected blood donors identified by screening with the Ab-
bott or Ortho second generation ELISA (33). Plasma sam-
ples were also obtained from 27 human immunodeficiency
virus-uninfected hemophiliacs who had been treated with
non-heat-inactivated factor VIII and IX concentrates and
who had been infected with HCV for several years. All
samples were anti-HCV positive by several second genera-
tion screening and confirmatory assays (13a, 56). Control
samples were obtained from anti-HCV-negative blood do-
nors. All samples from anti-HCV-positive blood donors
were screened for antibody to the recombinant clOO-3 re-
combinant protein using the Abbott first generation enzyme
immunoassay according to the manufacturer's instructions.
Sequence analysis of NS-4. RNA was extracted from a
series of HCV-infected blood donors and reverse transcribed
with a primer complementary in sequence to a relatively well
conserved segment within the region of the HCV genome
encoding NS-4. Complementary DNA was amplified by
using this primer in combination with a series of sense
orientation primers for each of the major types of HCV
(Table 1). The sequences of these primers were determined
by comparison of those obtained in the NS-3 region in a
previous study and other published sequences (7, 10, 23, 38,
46). The primary PCR product was amplified further by a
second PCR with a conserved antisense inner primer and
one of three type-specific sense primers for amplification of
HCV types 1, 2, and 3. Amplified DNA was directly se-
quenced as previously described (7).
HCV genotyping. HCV RNA sequences were reverse
transcribed and amplified from plasma samples of infected
blood donor samples as previously described (7). The HCV
type was determined either by direct nucleotide sequencing
of the PCR product and phylogenetic analysis (7) or by
restriction fragment length polymorphism analysis of radio-
labelled amplified DNA with HaeIII-RsaI and ScrFI (33).
Epitope mapping. Four sets of overlapping nonapeptides
corresponding to the consensus amino acid sequences of
HCV subtypes la, lb, 2b, and 3a were synthesized as
previously described (32) and modified for Fmoc chemistry
by using kits from Cambridge Research Biochemical (Nor-
wich, United Kingdom) according to the manufacturer's
instructions. Each series comprised a set of 82 oligopeptides
from positions 1679 to 1768 in the NS-4 region (10), each of
which overlapped the adjacent peptide by eight residues.
The peptides were synthesized in covalent linkage to poly-
propylene rods having the format and spacing of the wells in
a microtiter plate.
Antibody reactivity to individual peptides was assayed
with incubation of each pin overnight at 4°C in 175 ,ul of a
1/40 dilution of anti-HCV-positive or -negative plasma in
phosphate-buffered saline (PBS) supplemented with 1%
ovalbumin, 1% bovine serum albumin, and 0.1% Tween 20
overnight. Pins were washed in four changes of PBS-0.1%
Tween 20 (PBST), and bound antibody was detected by a
second incubation with a 1/20,000 dilution of affinity-isolated
horseradish peroxidase-conjugated anti-human immunoglob-
ulin G (Sigma Chemical Company, Poole, United Kingdom)
for 2 h at 20°C. After washing, pins were immersed in 100 ,ul
of a freshly prepared solution of 0.5 ,ug of 2,2'-azino-bis(3-
ethylbenzthiazoline 6-sulphonic acid) (Sigma) per ml in 0.1
M sodium phosphate-sodium citrate buffer (pH 4.0) contain-
ing 0.03% hydrogen peroxide (30 volumes) for 30 min at
20°C. Optical densities (ODs) were measured at 410 nm, with
a reference wavelength of 650 nm by using a dual-wave-
length spectrophotometer; values ranged from -100 to 750
mU. Pins were reused by stripping off antibody by sonica-
tion (30 min) in 1% sodium dodecyl sulfate-0.1% 2-mercap-
toethanol-0.1 M sodium dihydrogen orthophosphate, fol-
lowed by reblocking in 1% ovalbumin-1% bovine serum
albumin-0.1% Tween 20 in PBS for 1 h at room temperature.
Synthesis of branched peptides. Branched peptides (40, 47)
corresponding to antigenic regions identified by epitope
mapping were synthesized by continuous-flow Fmoc chem-
istry as previously described (3, 32). Some peptides were
made to contain an equimolar mixture of two amino acids at
one position (Table 2). To do this, the peptide was assembled
on a single batch of resin up to the relevant amino acid, at
which point the resin was split into two aliquots. One of the
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TABLE 2. Sequences of NS-4 peptides used for type-specific
serological assay
HCV Regiona Peptide Sequencetype
1 1 370-C KPA(I/V)IPDREVLYREFDEMb
1 370-B RPAV(I,V)PDREVLYQEFDEMb
2 373-C ECSQHLPYIEG(M/A)LAEQF
2 1 370-A RVVVTPDKEILYEAFDEM
2 373-A ECASRAALIEEGQRIAEIL
2 373-B ECASKAALIEEGQRMAEML
3 1 368-A KPALVPDKEVLYQQYDEM
2 368-B ECSQAAPYIEQAQVIAHQF
a Amino acid positions 1691 to 1708 (region 1) and 1710 to 1728 (region 2),
numbered as described in reference 10.
b Alternative peptides, where there is variability of an HCV type.
two amino acids was added to one aliquot, and the other was
added the second aliquot. The two portions of resin were
then combined, and the synthesis was continued. For cases
in which alternative variants showed two amino acid differ-
ences, peptides were produced separately to avoid synthesis
of hybrid sequences not present in the original samples (e.g.,
peptides 373-A and 373-B of HCV type 2). The amino acid
compositions of the branched peptides were determined by
amino acid analysis (Cambridge Research Biochemicals,
Cambridge, United Kingdom) and were in agreement with
expectations.
Indirect ELISA. Approximately 1 mg of peptide was
reconstituted in distilled water (dH2O) to give a final con-
centration of 1 mg/ml immediately before use. Peptides 368A
and 368B (type 3, regions 1 and 2) required acidification with
a small volume of acetic acid to ensure complete solubiliza-
tion, while the remainder was dissolved only after alkalin-
ization by bubbling 1 to 2 ml of ammonia vapor through the
water. One hundred-microliter volumes of peptides at con-
centrations ranging from 20 ng/ml to 20 ,ug/ml in PBS were
coated onto polypropylene microtiter wells (Immunoplate-
GIBCO BRL, Paisley, United Kingdom) overnight at 4°C.
After washing, the wells were blocked in 150-,ul volumes of
blocking solution (PBST-1% bovine serum albumin, 1%
ovalbumin) for 1 h at room temperature. Serological reactiv-
ity to an irrelevant branched peptide (HIV V3 loop [42]) was
measured for each serum, which served as a control for
possible nonspecific antibody binding to the polylysine
spacer residues.
Plasma from HCV-infected blood donors was diluted in
PBST-0.5% bovine serum albumin (PBSAT), and 100 ,lI was
added to antigen-coated and blocked wells. The first incuba-
tion was carried out at room temperature for 1 h. Plates were
washed four times in PBST, followed by incubation with
horseradish peroxidase-conjugated anti-human immunoglob-
ulin G (1/20,000 in PBSAT; 1 h, room temperature). The
plates were finally washed four times in PBST and incubated
with substrate (50 ,ug of o-phenylenediamine per ml, 0.1%
H202 [30 volumes]; 30 min at room temperature). ODs were
read at 490 nm, with values ranging from -100 to 2,000 mU.
Blocking assays were carried out as described above,
except that blocking peptide (in a 100:1 excess over those
used for coating microtiter wells) was added to the first
antibody diluent.
RESULTS
Derivation of NS-4 consensus sequences for HCV types 1 to
3. Part of the 5' noncoding region of HCV was amplified by
PCR from circulating viral RNA in plasma samples from 14
anti-HCV-positive Scottish blood donors. Direct sequence
analysis of the region allowed each sample to be assigned to
type 1 (n = 5), 2 (n = 4), or 3 (n = 5) variants by comparison
with previously published sequences (7). To amplify the
NS-4 region, cDNA was synthesized with primer 007 from
plasma viral RNA, amplified with this primer and the appro-
priate type-specific sense primer (Table 1), and then sub-
jected to a second reaction with primer 220 and primer 008,
509, or 196, depending on the HCV type. Direct sequence
analysis of the amplified DNA yielded nucleotide sequences
corresponding to positions 4911 to 5271 in the HCV type 1
prototype genome (10).
The inferred amino acid sequences (Fig. 1A) of variants
from the five blood donors infected with HCV type 1 were
similar to those of the prototype HCV type 1 variant
(subtype la [7]) and differed at several sites from sequences
of subtypes lb, 2a, and 2b (Fig. 1). One sequence from a type
2-infected donor was similar to that of type 2a, while the
remaining three were type 2b. The five donors with type 3
infection yielded NS-4 sequences distinct from any of those
published to date, further confirming its status as a separate
major type of HCV (7).
Within each subtype, remarkably little sequence variation
was apparent; only 8 polymorphic amino acids of 90 were
found among the type 1 sequences, and only 2 were found in
the five type 3 sequences. Furthermore, most of the substi-
tutions were between similar amino acids, such as substitu-
tions of arginine for lysine, valine for alanine, and valine for
isoleucine. From the type la, 2b, and 3 sequences, it was
possible to derive a consensus sequence that was represen-
tative of each subtype of HCV (Fig. 1B). However, these
consensus sequences differed considerably from each other
and from those of the two subtype lb and two subtype 2a
sequences, with only 36 amino acid residues of 90 being
conserved between all five subtypes.
The consensus sequences from types la, lb, 2b, and 3
were used to specify four sets of 82 overlapping peptides,
each of which was nine residues in length and overlapped
by eight residues. For example, the sequences of the pep-
tides of the subtype la series were CVVIVGRIV (first), VVI
VGRIVL (second), and VIVGRIVLS (third), etc., to FWA
KHMWNF, the last (82nd) peptide. The distribution of
changes between the amino acid sequences of the types la,
lb, 2b, and 3 resulted in almost all of corresponding peptides
in the four series having different sequences (Fig. 1B).
Serological reactivity between the subtype la peptides and
a plasma sample from a type 1-infected blood donor was
confined to three or four relatively well defined sequential
epitopes in the NSA region (Fig. 2A), spanning peptides 12
to 22 (region 1), 32 to 38 (region 2), and 52 to 55 (region 3).
Reactivity to peptides 12 to 20 and 32 to 38 was also found in
the three additional anti-HCV type 1 samples tested (data
not shown). In contrast, a sample from an anti-HCV-nega-
tive blood donor showed no significant reactivity with any of
the peptides in the subtype la series (Fig. 2E). Reactivity of
these sera to the subtype lb series of peptides was similar
both quantitatively and in antibody specificity to that of
subtype la (Fig. 2A and B). Reactivity of a type 2-infected
donor samples with the type 2b peptide series (Fig. 2C) and
of a type 3-infected donor with type 3 peptides (Fig. 2D) was
to regions corresponding almost exactly to those of regions 1
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A 1679 1699 17 19 173 9 1759 1768
v v
HCV-1 CVVIVGRVVLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQKLETFWAKHMWNF
T0016 CVVIVGRIVLSGKPAIIPDREVLYRE........... PYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQRLETF.
T0042 CVVIVGRIVLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQRLEAF.
T0077 CVVIVGRIVLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQRLEAFW .......
la T1801 CVVIVGRIVLSGKPAVIPDREVLYREFDEMEECSQHLPYIEQGMALAEQFKQKALGLLQTASRQAEVIAPAVQTNWQKLEAFWAK.
T1825 CVVIVGRIDLSGKPAVIPDREVLYREFDEMEECSQHLPYIEQGMALAEQFKQKALGLLQTASRQAEVITPWQTNWQKLEAFWAKHM...
Cons. CVVIVGRIVLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQRLEAFWAKHMWNF
l HCV-J SVVIVGRIILSGRPAVIPDREVLYQEFDEMEECASHLPYIEQGMQLAEQFKQKALGLLQTATKQAEAAAPVVESKWRALEVFWAKHMWNF
lb HCV BK SVVIVGRIILSGRPAIVPDRELLYQEFDEMEECASHLPYIEQGMQLAEQFKQKALGLLQTATKQAEAAAPVVESKWRALETFWAKHMWNF]
HC-J6 CVCIIGRLHVNQRAVVAPDKEVLYEAFDEMEECASRAALIEEGQRIAEMLKSKIQGLLQQASKQAQDIQPAVQASWPKVEQFWAKHMWNF|
2a T0351 CVSIIGRLHINQRAVIAPDKEVLYEAFDEMEECASRAALIEEGQRIAEMLRSKIQGLLQQASKQAQDIQPAVQASWPKVEQFW .......
HC-J8 CISIIGRLHLNDRVVVAPDKEILYEAFDEMEECASKAALIEEGQRMAEMLKSKIQGLLQQATRQAQDIQPAIQSSWPKLEQFWAKHMWNF
CloneA CVSIIGRLHLNDQVVVTPDKEILYEAFDEMEECASKAALIEEGQRMAEMLKSKIQGLLQQATRQAQDIQ.
T0059 CISIIGRLHLNDRVVVTPDKEILYEAFDEMEECASKAALIEEGQRMAEMLKSKIQGLLQQATRQAQDIQPVVQSSWPKLEQFWAKHMW..
2b T0940 CVSIIGRLHLNDRVVVTPDKEILYEA.......... AALIEEGQRMAEMLKSKIQGLLQQATRQAQDIQPWQSSWPKLEQFW .......
T0810 CISIIGRLHLNDRVVVAPDKEILYEAFDEMEECASKAALIEEGQRMAEMLKSKIQGLLQQATRQAQDIQPAVQSSWPKLEQFW.
Cons. CISIIGRLHLNDRVVVTPDKEILYEAFDEMEECASKAALIEEGQRMAEMLKSKIQGLLQQATRQAQDIQPVVQSSWPKLEQFWAKHMWNF
T0040 CVVIVGHIELGGKPAIVPDKEVLYQQYDEMEECSQAAPYIEQAQVIAHQFKEKVLGLLQRATQQQAVIEPIVATNWQKLETFWHKHM...
T0038 CVVIVGHIELGGKPALVPDKEVLYQQYDEMEECSQAAPYIEQAQVIAHQFKEKVLGLLQRATQQQAVIEPIVATNWQKLEAFWHKHM...
T0036 CVVIVGHIELGGKPALVPDKEVLYQQYDEMEECSQAAPYIEQAQVIAHQFKEKVLGLLQRATQQQAVIEPIVATNW..............
3 T0026 CVVIVGHIELGGKPALVPDKEVLYQQYDEMEECSQAAPYIEQAQVIAHQFKEKVLGLLQRATQQQAVIEPIVATNWQ.............
T1787 CVVIVGHIELGGKPALVPDKEVLYQQYDEMEECSQAAPYIEQAQVIAHQFKEKVLGLLQRATQQQAVIEPIVATNWQKLEAFWHKHM...
Cons. CVVIVGHIELGGKPALVPDKEVLYQQYDEMEECSQAAPYIEQAQVIAHQFKEKVLGLLQRATQQQAVIEPIVATNWQKLEAFWHKHM...
1 2 4 6 8 9
1 21 41 61 81 90
B 1 21 41 61 81 90
la Cons. CVVIVGRIVLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQRLEAFWAKHMWNF
lb HCV-J S- I----R--V--------Q--------AS---------Q----------------TK---AA----ESK-RA--V---------
lb HCV BK S-------I---R---V----L--Q--------AS---------Q----------------TK---AA-----ESK-RA--T---------
2a HC-J6
--C-I--LHVNQRAVVA--K----EA-------ASRAAL--E-QRI--ML-S-IQ----Q--K--QD-Q-A--AS-PKV-Q---------
2a T0351 ....... LHINQRAV-A--K----EA-------ASRAAL--E-QRI--MLRS-IQ----Q--K--QD-Q-A--AS-PKV-Q--..
2b Cons.
-IS-I--LH-NDRVVVT--K-I--EA-------ASKAAL--E-QRM--ML-S-IQ----Q-T---QD-Q----SS-PK--Q---------
3 Cons.
------H-E-G----LV--K----QQY--------AA-----AQVI-HI---E-V-----R-TQ-QA--E-I-A----K-----H---...
A L L ***I*G***********PD*E*LY*Q*DEMEEC******IE*****A*****K**GLLQ*A**Q*****P*V***W***E*FW*KHMWNF]
FIG. 1. Comparison of amino acid sequences of HCV types 1 to 3 in NS-4 region. (A) Intratypic variation. (B) Comparison of consensus
sequence of HCV types in NS-4 region. Only two samples from subtypes lb and 2a were obtained, and therefore both sequences are shown.
Residues are numbered according to those of HCV type 1 (10). The sources of the published sequences for the following are given in
parentheses: HCV type 1 (10), HCV-J (23), HCV-BK (46), HC-J6 (38), HC-J8 (37), clone A (50). Sequences T0016 to T1825 were derived from
Scottish blood donors. The HCV type is indicated in the left column. Variable amino acid residues are indicated in bold...., sequence has
not been determined; -, residue identical to that of HCV type 1 (10); *, polymorphic amino acid residues between HCV types; cons.,
consensus.
and 2 in type 1 and to further antigenic regions between 58
and 63, downstream from region 3 of type 1 (Fig. 2A and B).
Again, homologous type reactivity to regions 1 and 2 was
found in other type 2- and 3-infected donors (data not
shown). Despite the substantial sequence differences be-
tween the major types of HCV, the antigenic regions are
located in similar places in the NS-4 protein of all three HCV
types.
To investigate whether antibody elicited by infection with
one HCV type cross-reacted with epitopes of the other
types, serum samples from HCV-infected donors were incu-
bated with each of the three sets of heterologous type
peptides, and the reactivity was compared with that of the
homologous type antigens (Fig. 3). The sample from the type
1-infected donor showed weak reactivity to the first anti-
genic region of the type 2 and 3 peptides (Fig. 3D and G) but
showed equivalent reactivity with the subtype lb series of
peptides (Fig. 2B). The type 2 plasma sample again cross-
reacted with heterologous peptides in only the first antigenic
region (Fig. 3B and H), while the type 3 sample showed
weak reactivity with both the first and second regions of the
type 1 series and with region 1 of type 2 (Fig. 3C and F).
Further experiments with other sera confirmed that cross-
reactivity between types was variable and generally weaker
than that to homologous type peptides (data not shown).
As serological reactivity to antigenic regions 1 and 2 was
the most frequently found between the HCV types, the
consensus sequences for these regions were used to specify
a series of branched oligopeptides for the type-specific assay
(Table 2). The peptides from region 1 spanned peptides 13 to
22 in the mapping series (HCV residues 1691 to 1708), while
those of region 2 corresponded to the sequences of peptides
32 to 42 (residues 1720 to 1738). Sequence variation within
each type (Fig. 1A) was allowed for by synthesizing two
peptides, each bearing the alternative amino acid residues
(see Materials and Methods). For example, peptide 370-C
(Table 2) contains an equimolar mixture of two peptides, one
with isoleucine and the other with valine at position 4
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FIG. 2. Reactivity of representative anti-HCV-positive plasma samples (A to D) and a negative plasma sample (E to H) with overlapping
peptides (numbered 1 to 82) corresponding to sequences within the NS-4 region of HCV. Reactivity of samples from an HCV type 1-infected
donor (A and B) and an anti-HCV-negative donor (E and F) with peptides of subtype la (A and E) or lb (B and F) peptides; reactivity of a
type 2-infected donor (C) and anti-HCV negative donor (G) with type 2b peptides; reactivity of a type 3-infected donor (D) and anti-HCV
negative donor (H) with type 3 peptides. ODs are expressed in milliunits in the range of 125 to 750 mU.
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TABLE 3. Reactivity of anti-HCV-positive and -negative samples
to peptides corresponding to two antigenic regions in NS-4
No. of reactive
HCV type(s) Antigenic Peptide samples' Total no.region
1 2 3
1 1 370-C 39b 3 24 66
1 370-B 40 3 18 61
2 373-C 46 3 10 59
2 1 370-A 35 6 17 58
2 373-A 24 7 2 33
2 373-B 0 7 2 9
3 1 368-A 39 6 25 70
2 368-B 39 1 30 70
1+2+3 1+2 ALL 48 7 35 90
1 1+2 c100-3c 43 3 15 61
Total no. 49 9 37 95
tested
a Number of reactive samples from blood donors subdivided according to
infection with types 1, 2, or 3.
b Type-homologous reactions are indicated in boldtype.
c Reactivity with commercially available recombinant clOO-3-type antigen.
(residue 1694). The amount of branched peptide used for the
ELISA was determined by a series of checkerboard titra-
tions of peptide with anti-HCV-positive and -negative sera.
Virtually no nonspecific binding to peptides was found, even
at the highest concentration of peptides tested (10 ,ug per
well) and the highest plasma concentration (1/10) (data not
shown). For subsequent assays, we used a coating antigen
concentration of 1 ,ug of antigen per ml and a test dilution of
serum or plasma of 1/40.
For the ELISA, the cutoff value for each peptide was
calculated as the mean of four negative-control values (re-
activity to HCV peptide minus reactivity to irrelevant [non-
HCV] peptides) + 2 standard deviations and ranged from 13
to 105 mU. We found that all 26 samples from anti-HCV-
negative blood donors yielded net OD values (that of HCV
peptide minus that of irrelevant peptides) below this cutoff
value, while samples from HCV-infected blood donors
showed frequent reactivity with each of the NS-4 peptides
(Table 3). OD values ranged continuously from just above
the cutoff to >2,000 mU. In general, reactivity to type
homologous peptides was more frequent than that to other
HCV types; in particular, very few sera from type 1- and
type 3-infected donors reacted with peptides corresponding
to the second antigenic region of type 2 (peptides 373-A and
373-B). In contrast, high frequencies of cross-reactivity were
observed between HCV types 1 and 3 in both antigenic
regions; 39 of the 49 type 1 samples reacted with type 3
antigens, while 30 of the 37 type 3 samples reacted with type
1 peptides. A total of 95% of anti-HCV-positive samples
showed significant reactivity in an ELISA for which wells
were coated with all eight peptides, substantially higher than
that achieved with the recombinant clOO-3 antigen (61 of 95)
and higher than the frequency of reactivity with any one
NS-4 peptide used alone (maximum, 70 of 95, peptides 368-A
and 368-B; Table 3).
The ELISA was modified in order to detect type-specific
antibody by the addition of a blocking concentration of
peptides to plasma or serum samples to absorb cross-
reactive antibody. In the HCV type-specific antibody assay
(HCV-TSAA), wells were coated with 100 ng of peptides
corresponding to each of the three HCV types per ml. The
first well was coated with the three type 1 peptides, the
second contained the three type 2 peptides, and the third
well was coated with the two type 3 peptides. Test samples
at a 1/40 dilution were incubated in each of the three wells in
the presence of a 100:1 molar excess of type heterologous
peptides in solution. Thus, for the well coated with type 1
peptides, the test sample was diluted in buffer containing 10
,ug of each of the three type 2 peptides and the two type 3
peptides per ml. The net effect of this blocking is to ensure
that the only antibody that could bind to the antigens on the
solid phase was one that reacted with epitopes not shared
with other HCV types. Type-specific reactivity was consid-
ered significant when it was greater than twice the residual
OD obtained from incubating the test serum in a well coated
with all eight peptides and blocked with all eight.
To illustrate how the method may be used for serological
typing of HCV infection, the OD values of a series of
representative samples in the three type-specific wells and
the blocked and unblocked controls are shown graphically in
Fig. 4. Four samples from blood donors infected with HCV
type 1 (Fig. 4A to D) show variable reactivity with the
unblocked well coated with all eight peptides (first bar
[labelled C] in each histogram). Blocking with all eight
reduced binding in all cases to background levels (<100 mU
[second bar]). Reactivity to the type 2 and type 3 peptides on
their own could also be completely blocked (fourth and fifth
bars, respectively), while type 2 and 3 peptides in solution
failed to block reactivity to the type 1 antigens (third bar).
From this data, we can infer that the four samples illustrated
contain antibody solely to HCV type 1. Equivalent results
were obtained with the four type 2 and four type 3 serum
samples (Fig. 4). Comparison of the OD of unblocked
control with that of the blocked homologous type antigen
showed that the type-specific antibody formed a substantial
proportion and usually the majority of the total anti-NS-4
peptide antibody within each sample.
A total of 137 samples from donors typed by restriction
fragment length polymorphism analysis of sequences ampli-
fied by PCR in the 5' noncoding region (33) were assayed
blind for the presence of type-specific antibodies by using
the HCV-TSAA (Table 4). Upon decoding the results, we
observed a remarkable correlation between the results of the
two assays. Almost all samples that could be serologically
typed contained antibody of a single type specificity corre-
sponding to the HCV type detected by PCR (118 of 122).
Antibody to one of the HCV types found in the four samples
with dual specificity also corresponded to the circulating
HCV type identified by PCR. Only 15 samples could not be
typed; 7 were nonreactive with the NS-4 antigens at either
1/40 or upon retesting at a 1/10 test dilution, while the
remaining 8 contained no detectable type-specific antibody.
These samples showed (usually weak) reactivity with the
unblocked peptides, that was completely blocked out not
only by all eight peptides together but also in each of the
wells blocked with heterologous peptides, indicating that
these samples contain insufficient type-specific antibody.
To investigate whether the HCV-TSAA could reliably
detect infection with multiple HCV types, we screened
samples from 27 HCV-infected hemophiliacs treated for
several years with non-heat-treated factor VIII or IX and
who had been potentially exposed to all three types of HCV
over the years of treatment (18, 27, 56). We found that a
higher proportion of samples showed type-specific antibody
to multiple HCV types. Whereas in blood donors, only 4
(3%) of 122 samples showed evidence of multiple infection,
and dual or even triple antibody specificities were found in 8
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FIG. 4. Reactivity of representative plasma samples from donors of known HCV type in HCV-TSAA. Samples from HCV type 1 (A to
D)-, type 2 (E to H)-, or type 3 (I to L)-infected donors. The histograms show reactivity to all eight peptides, with no blocking (total anti-NS-4
reactivity bar labelled (C); all eight peptides blocked with all eight (blocked control) (bar labelled 1+2+3): type 1 peptides blocked with type
2 and 3 peptides (type 1-specific antibody) (bar labelled 1); type 2 peptides blocked with type 1 and 3 peptides (type 2-specific antibody) (bar
labelled 2); and type 3 peptides blocked with type 1 and 2 peptides (type 3-specific antibody) (bar labelled 3).
(40%) of the 20 hemophiliac samples typed by HCV-TSAA
(Table 4). Antibodies to types 1 and 3 were found most
frequently in the hemophiliacs, most of whom had been
treated with only factor VIII or IX concentrates derived
from local plasma donations. This frequency of antibody
types is consistent with previous observations these two
types are the predominant HCV variants detected in Scottish
blood donors (33).
DISCUSSION
Epitope mapping of NS-4. In this study, we have investi-
gated the antigenicity of the NS-4 protein of HCV. Two
major sequential antigenic determinants occurred at similar
positions within the NS-4 sequences of HCV types 1, 2, and
3 and coincided with substantial sequence differences be-
tween the HCV types. For example, the consensus subtype
la sequence of the first antigenic region (residues 1691 to
1708) differed from subtype 2b at 9 of the 18 amino acid
residues and from type 3 by 6 residues. In the second
antigenic region (1710 to 1728), sequences of types la, 2b,
and 3 differed from each other by 7 to 12 of 19 residues. This
amino acid sequence diversity implies substantial type-
specific differences in antigenicity between peptides corre-
sponding to the two regions, which is consistent with the
absence of serological reactivity of most sera from HCV
type 2- and 3-infected individuals to the recombinant protein
5-1-1 (8, 33), which extends from residues 1694 to 1736 and
therefore includes part of the first antigenic region and all of
the second (20). Similar type-specific reactivity has been also
observed with the longer clOO-3 protein, which includes all
of these residues, those upstream in NS-3, and those down-
stream towards the end of NS-4; residues between 1679 and
1768 probably comprise the major antigenic region. The
A
B
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5-1-1 region has been previously shown to be the target of
the human monoclonal antibodies derived from an HCV-
infected individual (5). Reactivity of sera from HCV-infected
individuals to a series of overlapping peptides in the 5-1-1
region was normally restricted to peptides containing se-
quences corresponding to the first antigenic region described
in this paper. However, as the HCV genotype of the study
patients was not determined, it is possible that the infrequent
reactivity to the second antigenic region resulted from a lack
of cross-reactivity (Table 3) rather than an absence of
antibody (5).
Serological reactivity to several branched peptides corre-
sponding to the two antigenic regions was more frequent
than that of the HCV type 1 clOO-3 protein used in the
original assays for anti-HCV (Table 3). Of the 95 donations
screened, 61 showed reactivity with clOO-3, compared with
between 66 and 70 for individual HCV peptides from the first
antigenic region of HCV type 1 and regions 1 and 2 of HCV
type 3. Two factors undoubtedly contribute to this increased
rate of detection. Firstly, oligopeptides sometimes act as
antigens better than do recombinant proteins. This is illus-
trated by the increased rate of detection of anti-NS-4 anti-
body in recently developed third generation assays that use
a series of NS-4-encoded peptides in place of clOO-3 (13a,
25). Secondly, the peptides used in this study were synthe-
sized on a branched polylysine core (40, 47). The presenta-
tion of a polyvalent target allows smaller amounts of anti-
bodies to be detected than can be with the equivalent
monomeric peptide (48). The increased sensitivity may arise
from higher-affinity (i.e., multisite) binding of antibody to
branched peptide antigen (30), reduced physical constraints,
and greater binding of the branched peptides to the solid
phase (48). When sera were assayed with all eight peptides
from all three HCV types, antibodies were detected in 90 of
the 95 samples tested. This combination of peptides is
therefore as effective as the recombinant c22-3 (core region)
protein for detecting antibody to HCV (33, 56). In combina-
tion with other proteins, the NS-4 peptides described in this
paper are likely to be of major value in screening assays for
anti-HCV.
The serological response to HCV infection is very vari-
able, with often a delayed appearance of antibody to the core
protein in cases of posttransfusion NANBH (52). Therefore,
in many cases, antibody to the more variable nonstructural
proteins, such as c33c, clOO-3, and 5-1-1, may be the only
evidence of infection, particularly in individuals who are
marginally (human immunodeficiency virus-negative hemo-
philiacs and renal dialysis patients) or severely immunosup-
pressed (human immunodeficiency virus-infected individuals
[56] and transplant recipients). The absence of serological
cross-reactivity between antibody elicited by infection with
divergent HCV types with the nonstructural proteins in
current anti-HCV assays may therefore be one explanation
for the continued finding of NANBH patients and blood
donors who are antibody negative but positive by PCR and
who have been implicated in transmission of HCV by
transfusion (1, 19, 45).
Detection of type-specific antibody. The amino acid se-
quences of the antigenic regions of the three HCV types
differed considerably from each other, and it was originally
anticipated that serological reactivity to them would be type
specific. However, substantial degrees of cross-reactivity
were observed upon epitope mapping (Fig. 2) and ELISA
with branched peptides (Table 3). To detect type-specific
antibody, it was necessary to absorb cross-reactive antibody
with a molar excess of heterologous peptides in solution, on
TABLE 4. Comparison of serological typing by HCV-TSAA
with PCR
No. of No. of samples with the indicatedHCV type samples type-specific antibody:
tested 1 2 3 1+2 1+3 2+3 1+2+3 NTSb NRC
1 68 61 0 0 0 1 0 0 3 3
2 13 0 11 0 0 0 1 0 1 0
3 56 1 0 45 0 2 0 0 4 4
Hemd 27 10 0 2 1 6 0 1 2 5
a Genotype of HCV sequences amplified by PCR and typed by restriction
fragment length polymorphism (33); none, untypeable samples from HCV-
infected hemophiliacs.
b NTS, no type-specific antibody detected.
c NR, nonreactive with NS-4 peptides.
d Samples from HCV-infected hemophiliacs, untyped by PCR.
the basis that the only antibody that could bind to the solid
phase was that which reacted with epitopes not shared with
other HCV types. In general, the circulating HCV "geno"-
type detected by PCR in samples from HCV-infected blood
donors corresponded to the detection of type-specific anti-
body to the corresponding HCV "sero"-type (Table 4). The
detection of dual antibody specificity in samples from four
donors suggested that they had been exposed and infected
with more than one HCV type; in such cases, the PCR type
corresponded to one of the HCV types for which type-
specific antibody was detected. A total of 122 (89%) of 137
blood donor samples were successfully typed, of which all
but one were consistent with HCV genotyping by PCR.
Although the serological assay for type-specific antibody to
different HCV types does not necessarily reflect actively
replicating virus in cases of recent infection, it is obviously a
practical alternative to current PCR-based typing assays (14,
33, 36, 39) in the majority of circumstances and the only
possible assay in those who are anti-HCV positive but
negative by PCR. At a practical level, it costs virtually
nothing to carry out, uses standard laboratory equipment,
requires small volumes of sera, and could be used on old or
incorrectly stored samples in which the RNA has degraded
(13).
Type-specific antibody to a short peptide antigen of the
core protein has also been described, allowing those samples
that were reactive to be differentiated into anti-HCV type 1
and type 2 (28). However, this assay could serologically type
a smaller proportion of samples (36 of 56) than the anti-NS-
4-based assay described here, and the assay would be
unlikely to function correctly with samples from individuals
infected with other HCV types, such as type 3. The type-
specific core peptide of type 1 differed by only 2 residues
from the corresponding peptide sequence of type 3, both of
which were conservative replacements of uncharged amino
acids for other uncharged amino acids, comparing unfavor-
ably with the six differences between type 1 and type 2 core
peptide sequences (28). Furthermore, an essential element of
the HCV-TSAA described herein is the blocking step that
serves to absorb cross-reactive antibody. It is therefore
capable of detecting a minority component of type-specific
antibody against a background of cross-reactive antibody,
providing a stringent assay for dual or even triple antibody
specificities.
In this study, we found that almost all blood donors had
antibody to only a single type. In some ways, this is
surprising in view of previous observations that the major
risk factor for HCV infection in this particular group of blood
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donors is past intravenous drug abuse by needlesharing and
that both HCV types 1 and 3 are approximately equally
prevalent in this particular risk group in Scotland (33). A
higher rate of multiple infection was detected in hemophili-
acs treated with noninactivated factor VIII or IX (40%),
higher than that detected by PCR-based typing of circulating
RNA sequences (39), but which still does not reflect the full
extent of their exposure to HCV over the years of treatment
with factor VIII. It is possible that past infection with HCV
completely or partially protects the individual from further
infection or attenuates the secondary immune response to
the extent that type-specific antibody to the reinfecting virus
type remains undetectable. Evidence that previous exposure
modifies the course of disease upon reinfection is provided
by experimental cross-challenge experiments in chimpan-
zees (17, 41). In many cases, challenge of previously infected
chimpanzees to HCV appeared to lead to reinfection, but
this was accompanied by only a slight elevation of alanine
aminotransferase levels and infrequent clinical hepatitis.
Furthermore, it is not clear whether the material used for the
challenge experiments reflects that of normal human expo-
sure. The infectious dose of HCV in clotting factor and in
shared needles from intravenous drug abusers is likely to be
relatively low, and reinfection in these risk groups may
therefore be correspondingly rarer than that in animal mod-
els.
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